

Robert N. Burstein, DDS Receives Exclusive ACE™ Certification in the Diagnosis and Treatment of Periodontal Disease

South Windsor, CT- April 3, 2008 – Robert N. Burstein, DDS recently received ARESTIN® Certified Expert (ACE™) certification after completing comprehensive training on the diagnosis and treatment of periodontal disease.

The exclusive ACE™ certification is important to residents of South Windsor because periodontal disease is the most common chronic bacterial infection in adults, affecting 35.7 million Americans,¹ and is the leading cause of adult tooth loss.² In addition, the Surgeon General has issued a warning³ regarding the possible relationship between periodontal disease and a variety of medical conditions, including cardiovascular disease, diabetes, and osteoporosis.

“Knowing the negative impact periodontal disease that is left untreated can have on the oral health and general health of my patients prompted me to enroll in the ACE™ certification training,” said Dr. Robert N. Burstein. “This important and comprehensive periodontal disease diagnosis and treatment training program enables me to continue providing my patients with the highest standard of care available.”

ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is a locally administered antibiotic (LAA) manufactured by OraPharma, Inc. Clinical studies have proven that ARESTIN® used as an adjunct to scaling and root planing (SRP) is more effective than SRP alone in eliminating periodontal pathogens.⁴

SRP is a manual procedure that is performed by a dentist or registered dental hygienist, whereby bacterial pathogens residing in the plaque and tartar are removed from below the gum line while smoothing the tooth’s root surfaces to promote healing and prevent plaque from again taking hold.

During SRP, many dentists prescribe or administer an LAA to treat the periodontal infection and promote healing. One such LAA is OraPharma’s ARESTIN®. According to Dr. Robert N. Burstein, “ARESTIN® is an effective antibiotic that kills the bacteria that cause periodontal disease.”

In order to earn ACE™ certification, Dr. Robert N. Burstein was trained and tested in the following areas: accurate diagnosis of periodontal disease, effective treatment protocol,

accurate insurance coding, the benefits of using LAAs, staff and patient education, encouraging patient compliance, patient monitoring, and the possible systemic health risks of untreated periodontal disease.

About Dental Office:

After receiving his B.S. in Biology from Indiana University, Dr. Burstein earned his dental degree from the SUNY – Buffalo School of Dental Medicine. He completed his general practice residency at Mount Sinai Hospital.

In practice for 16 years, Dr. Burstein is a member of the American Dental Association, Academy of General Dentistry, Hartford Dental Society, American Academy of Cosmetic Dentistry, American Academy of Oral Implantologists and the International Congress of Oral Implantologists.

About OraPharma, Inc.:

OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN[®] (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planning (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN[®] may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing. ARESTIN[®] contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth. The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.

1. Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. *J Periodontol* 1999;70:13-29.
2. Lewis C. Fighting gum disease: how to keep your teeth. *FDA Consum* 2002;36:16-22.
3. US Department of Health and Human Services. *Oral Health in America: A Report of the Surgeon General*. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health; 2000.
4. Goodson JM. Antimicrobial Efficacy of Arestin in Periodontitis Therapy. Presented at the 35th Annual Meeting of the American Association for Dental Research; March 8-11, 2006; Orlando, FL.

The decision to administer ARESTIN[®] is made solely by the healthcare professional.

ARESTIN[®] is a registered trademark of OraPharma, Inc./ACE[™] is a trademark of OraPharma, Inc./© OraPharma, Inc. 2007

A-549-07 6/07